Skip to main content
. 2013 Sep 3;33(10):761–771. doi: 10.1007/s40261-013-0126-5

Table 1.

Lead-in study treatment assignment and final dose for patients who entered the extension study

Lead-in study Placebo Levomilnacipran ER
40 mg/day 80 mg/day 120 mg/day
Study 1 (assigned fixed-dose) 107 97 83 89
Study 2 (final flexible dose) 125 29 23 46
Study 3 (final flexible dose)a 124 26 26 48

ER extended-release

aIn study 3, a final daily levomilnacipran ER dose of 20 or 160 mg was inadvertently taken by one patient each; these two patients were not included in the final dose count